Anygen Co., Ltd.

Gwangju Institute of Science and Technology

Chembridge Research Laboratories, Inc.

Yong-Chul Kim

Jung-Hoon Yoon

Jung-eun Lee

Donatella Chianelli

Jae In Kim

Sang Kook Lee

Hyun You

Sang-Gun Ahn

Hyo-Eun Yoon

Thomas Webb

Tae Sung Kim

Kwan-Young Jung

Soo-Ho Ban

Si Wouk Kim

Hyo Jin Ko

Myoung Ju Moon

Soon-Young Jeong

Jae-Il Kim

Joong Heui Cho

Soo-Jeong Choi

Chul-Seung Park

Tal-Soo Ha

Provided are a novel pyridine carboxylic acid based compound used as a P2Xand P2Xreceptor antagonist, a production method for the same and a composition comprising the same. The compound according to the present invention is a powerful antagonist of P2Xand P2Xreceptors, and hence can be used as a drug for treating or preventing diseases involving neurological pain or chronic inflammatory diseases which are diseases caused by P2Xand P2Xreceptor activity.

Pyridine carboxylic acid based compound used as a P2X1 and P2X3 receptor antagonist, a production method for the same and a composition comprising the same

The present invention relates to a pheophorbide-&#x3b1; conjugate or its salt, solvate or hydrate. The pheophorbide-&#x3b1; conjugate of the present invention exhibiting fluorescence upon its introduction into cells and degradation inhibits the survival of various cancer cells. Especially, the conjugate of pheophorbide-&#x3b1; (1) and doxorubicin shows higher fluorescence intensity at lower pH (cancer environment). Therefore, the present composition for photodynamic therapy (PDT) of cancers is also very useful in detecting cancers. Interestingly, the anticancer effects of the present composition are dually exerted with help of both the photosensitizer and the anticancer drug of the present conjugates. 

Pheophorbide-&#x3b1; conjugates and their uses

The present invention relates to an indirubin-3'-oxime derivative as potent cyclin dependent kinase inhibitor with anti-cancer activity. More particularly, this invention relates to an indirubin-3&#x2032;-oxime derivative as potent cyclin dependent kinase inhibitor having excellent anti-cancer activity against human lung cancer cell, human fibro sarcoma cell, human colon cancer cell, human leukemia cell, human stomach cancer cell, human nasopharyngeal cancer cell and/or human breast cancer cell.

Indirubin-3'-oxime derivatives as potent cyclin dependent kinase inhibitors

The object of the present invention is to provide a potassium channel opener having benzofuroindole skeleton representing the following formula (I) wherein, Ris hydrogen, Ris CF, Ris COOH, Ris hydrogen, Ris hydrogen or chloride and Ris hydrogen or chloride.  

Potassium channel opener having benzofuroindole skeleton

The present invention relates to an indirubin derivative having anticancer property by inhibiting cell proliferation as to human cancer cell line. More particularly, this invention provides the synthesis of indirubin derivative known as CDK(Cyclin-dependent kinase) inhibitor. Further, inhibition activity of proliferation as to human cancer cell line and apoptosis against induced-differentiation of said indirubin derivative are researched to develop a novel indirubin derivative having efficacious anticancer properties as to various human cell lines.

Indirubin derivatives having anticancer property against human cancer cell line

Compounds having somatostatin activity of the following Formula I,wherein,

Somatostatin analogue compounds

Growing community of inventors

Gwangju, South Korea

Yong-Chul Kim